SEARCH RESULTS

1730 RESULTS

Risvodetinib

THERAPEUTICS Inhibikase Therapeutics, Inc. IkT-148009 Small Molecule alpha-synuclein Other Between February 2021 and January 2023, Inhibikase ran a Phase 1 single- and multiple-ascending-dose trial. The study enrolled 108 participants, and tested nine single doses fro

Current Filters

  • Date Range : Past 30 Days x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE